Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
Ennio Giulio FavalliLuigi SinigagliaAndrea BeccioliniVittorio GrossoRoberto GorlaChiara BazzaniFabiola AtzeniPier C Sarzi PuttiniEnrico FusaroRaffaele PelleritoRoberto CaporaliPublished in: International journal of rheumatic diseases (2017)
Our real-life data confirmed switching to a second TNFi as a good option for treating first-line TNFi failures in RA, especially in combination with sDMARDs. Second-line golimumab showed an overall better 2-year drug survival compared with adalimumab and etanercept.
Keyphrases
- rheumatoid arthritis
- ankylosing spondylitis
- disease activity
- electronic health record
- interstitial lung disease
- big data
- ulcerative colitis
- rheumatoid arthritis patients
- juvenile idiopathic arthritis
- machine learning
- data analysis
- adverse drug
- drug induced
- systemic lupus erythematosus
- artificial intelligence
- free survival